No Data
No Data
Is Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) Recent Stock Performance Tethered To Its Strong Fundamentals?
We Think That There Are More Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Than Just Sluggish Earnings
Huakang Co., Ltd. Semi-Annual Report 2024
Summary of Hua Kang Corporation's 2024 interim report
Huakang Corporation (605077.SH) has granted 0.845 million reserved restricted stocks to incentive recipients.
On August 21st, GeLongHui announced that Huakang Co., Ltd. (605077.SH) has agreed to reserve 0.845 million restricted stocks to be granted to 25 incentive targets on August 21, 2024, at a price of 9.14 yuan per share.
Huakang Co., Ltd. (605077.SH): The net income in the first half of the year was 0.138 billion yuan, a decrease of 25.27% year-on-year.
GeLunHui August 21st, HuaKang Shares (605077.SH) announced its 2024 interim report, reporting a revenue of 1.359 billion yuan, a decrease of 0.73% year-on-year; net income attributable to shareholders of the listed company was 0.138 billion yuan, a decrease of 25.27% year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.13 billion yuan, a decrease of 32.20% year-on-year; basic earnings per share was 0.46 yuan. The decrease in net income was mainly due to the amortization of stock-based incentives and an increase in construction period expenses for the Zhoushan HuaKang project during the current period.
No Data
No Data